We have read with great interest the article by Olsen et al. on the VALUE trial [1], which investigated the comparative effectiveness of valsartan versus amlodipine in reducing the incidence of end-stage renal disease (ESKD). This study provides valuable insights into hypertension management for patients at high cardiovascular and renal risk. The results indicate that valsartan and amlodipine had similar effects on ESKD incidence, and achieving a target systolic blood pressure (SBP) of <135 mmHg was highly effective in protecting kidney function.
